Replies

1 posted on 02/07/2022 6:03:39 AM PST by RaceBannon

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

https://pubmed.ncbi.nlm.nih.gov/32971268/

Mingyang Tang 1, Xiaodong Hu 2, Yi Wang 3, Xin Yao 4, Wei Zhang 5, Chenying Yu 6, Fuying Cheng 7, Jiangyan Li 8, Qiang Fang 9
Affiliations expand
PMID: 32971268 PMCID: PMC7505114 DOI: 10.1016/j.phrs.2020.105207
Free PMC article
Abstract
Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.

Keywords: avermectin(PubChem CID：6434889); cancer; doramectin(PubChem CID：9832750); drug repositioning; ivermectin; ivermectin(PubChem CID：6321424); moxidectin(PubChem CID：9832912); selamectin(PubChem CID：9578507).

2 posted on 02/07/2022 6:05:27 AM PST by RaceBannon (Rom 5:8 But God commendeth his love toward us, in that, while we were yet sinners, Christ died for )

https://pubmed.ncbi.nlm.nih.gov/29511601/

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
Mandy Juarez 1, Alejandro Schcolnik-Cabrera 1, Alfonso Dueñas-Gonzalez 2
Affiliations expand
PMID: 29511601 PMCID: PMC5835698
Free PMC article
Abstract
Drug repositioning is a highly studied alternative strategy to discover and develop anticancer drugs. This drug development approach identifies new indications for existing compounds. Ivermectin belongs to the group of avermectins (AVM), a series of 16-membered macrocyclic lactone compounds discovered in 1967, and FDA-approved for human use in 1987. It has been used by millions of people around the world exhibiting a wide margin of clinical safety. In this review, we summarize the in vitro and in vivo evidences demonstrating that ivermectin exerts antitumor effects in different types of cancer. Ivermectin interacts with several targets including the multidrug resistance protein (MDR), the Akt/mTOR and WNT-TCF pathways, the purinergic receptors, PAK-1 protein, certain cancer-related epigenetic deregulators such as SIN3A and SIN3B, RNA helicase, chloride channel receptors and preferentially target cancer stem-cell like population. Importantly, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients. Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients.

Keywords: Ivermectin; cancer; drug repurposing.